Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
NCT03051217Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2017
- Primary completion
- Nov 2018
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in psoriasis, generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) (3 arms), sponsored by UCB. Primary endpoint: Percentage of Subjects Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index at 16 weeks. Started Feb 2017; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
psoriasisgeneralized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on NCT03051217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051217.